Tokyo, May 2, 2011 (JCN) - Kaneka Corporation has confirmed the effects of the reduced form of CoQ10 (Ubiquinol) to improve the daily physical activity and the mental health in middle-aged and elderly women.
The study was conducted in collaboration with Dr. Kazuhiro Shimizu, an assistant professor of the Faculty of Sport Sciences, Waseda University and a research fellow of Graduate School of Comprehensive Human Sciences, University of Tsukuba.
The findings were presented in "The 21st Annual Meeting of Japanese Society of Clinical Sports Medicine" held in the Tsukuba International Congress Center on November 6th and 7th, 2010.
Kaneka reported in 2008 that Ubiquinol administration (100mg/day for 6 months) helped to improve the fatigue and the depression level in elderly people in the open label study conducted in collaboration with Tokyo Women's Medical University.
Forty-six healthy female subjects (average age 63.7 +/- 1.7 years old) were allocated randomly into the two groups of Ubiquinol (23 subjects) and placebo (23 subjects), and daily took Ubiquinol (150mg/day) or placebo for 8 weeks.
Before and after the treatment, the daily step count and consumed energy were measured for 2 weeks using a pedometer- instrument. In addition, physical and mental health states were measured by using SF-36 Health Survey.
The eight-week treatment with Ubiquinol showed significant improvement in the step count, reflecting physical activity, and mental health scores by using SF-36 (22% and 10%, respectively, compared before the treatment). There was no improvement in physical health evaluated by SF-36.
However, it is considered that physical health would be improved in long term treatment, because the physical activity evaluated by pedometer-like instrument showed significant effect.
The improvements of mental health (such as, the fatigue, the depression level, etc.) and the activity in elderly people are also expected to contribute to the reduction in work load for the care of the elderly.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Kaneka Confirms Positive Effect of Q10 Against Fatigue
(Dec 3, 2012)
|
|
|
Kaneka and Belgium's imec Develop Next-Generation Heterojunction Solar Cells
(June 14, 2012)
|
|
|
Kaneka Builds Plant in Malaysia for Production of PI Film
(Apr 21, 2012)
|
|
|
Kaneka to Establish Umbrella Hubs in Asia and the Americas
(Mar 12, 2012)
|
|
|
AGC, ADEKA and Kaneka to Withdraw Investments from Kashima Denkai and Kashima PVC Monomer
(Dec 21, 2011)
|
|
|
Kaneka, MOL and Mitsui Form CPVC JV in India
(Dec 7, 2011)
|
|
|
Kaneka Develops High-efficiency Heterojunction Silicon Solar Cell
(Nov 28, 2011)
|
|
|
Kaneka Sets Up Base in South Korea
(Nov 23, 2011)
|
|
|
Kaneka Trials Production System for 100% Plant Based Biopolymer Product
(May 14, 2011)
|
|
|
Kaneka Confirms the Effects of Reduced CoQ10 on Mental Health and Physical Activity
(May 2, 2011)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Biotech news...
|
|
